Abata Therapeutics

Medical Director, Clinical Development - Dermatology

Remote

Not SpecifiedCompensation
Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Pharmaceuticals, HealthcareIndustries

Requirements

Candidates must possess an MD and have at least 2 years of industry experience as a medical monitor and/or medical director. Experience in clinical development within Immunology & Inflammation therapeutic areas, particularly dermatology, allergy, or rheumatology, is required, along with experience in phase 2 and 3 clinical studies. The ideal candidate will be a highly motivated team player with effective communication skills, a growth mindset, and the ability to travel approximately 15%.

Responsibilities

The Medical Director will serve as a medical monitor, overseeing study execution in collaboration with the CRO, clinical operations, and pharmacovigilance, including safety reporting and medical monitoring plans. Responsibilities include supporting trial design, protocol development, and start-up activities for dermatology clinical studies. The role involves overseeing day-to-day clinical and medical execution, partnering with cross-functional teams for timely execution, and collaborating with clinical operations on site selection and CRO management. Additionally, the Medical Director will partner with medical affairs to build relationships with PIs and serve as the primary medical point of contact for sites and PIs.

Skills

Clinical Development
Medical Monitoring
Protocol Development
Clinical Strategy
Dermatology
Biotechnology
Pharmacovigilance
CRO Management

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters
2021Year Founded
$184.8MTotal Funding
EARLY_VCCompany Stage
BiotechnologyIndustries
11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.
Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.
Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.
Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.
Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.
FDA's accelerated approval pathways may expedite Abata's clinical trials.
Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI